Search This Board: 
Created: 06/17/2008 12:49:14 PM - Followers: 194 - Board type: Free - Posts Today: 0




Rexahn Pharmaceuticals Inc. (NYSE MKT: RNN) is a clinical stage biopharmaceutical company focused on developing best-in-class therapeutics for the treatment of cancer. Rexahn’s clinical development programs directly target specific proteins that are selectively expressed in human cancer cells, resulting in increased efficacy and reduced toxicity. In preclinical studies these drug candidates are effective against multiple drug resistant cancers and have shown to increase the effectiveness of various FDA approved cancer treatments. Rexahn is also developing specific biomarker tests that will help identify which patients will be most responsive to its treatments. The Company’s nanotechnology-based drug delivery system has shown it can make FDA approved chemotherapy drugs more effective.

Our clinical development pipeline consists of three novel compounds:

RX-3117 is a novel, oral, small molecule nucleoside compound.  Once intracellularly activated (phosphorylated) by the enzyme UCK2, it is incorporated into the DNA or RNA of cells and inhibits both DNA and RNA synthesis, which induces apoptotic cell death of tumor cells.  Because UCK2 is overexpressed in multiple human tumors, but has a very limited presence in normal tissues, RX-3117 offers the potential for a targeted anti-cancer therapy with an improved efficacy and safety profile, and we believe it has therapeutic potential in a broad range of cancers, including pancreatic, bladder, colon, and lung cancer.  RX-3117 has received “orphan drug designation” from the U.S. Food and Drug Administration (“FDA”) and from the European Commission (“EC”) for pancreatic cancer.

RX-5902 (Supinoxin™) is a potential first-in-class small molecule inhibitor of phosphorylated-p68, a protein that we believe plays a key role in cancer cell growth, progression and metastasis through its interaction with beta-catenin.  Phosphorylated p68, which is highly expressed in cancer cells, but not in normal cells, results in up-regulation of cancer-related genes and a subsequent proliferation of cancer cells and tumor growth.  RX-5902 selectively blocks the interaction of phosphorylated p68 with beta-catenin, thereby decreasing the proliferation or growth of cancer cells in preclinical models.  In addition, multiple pre-clinical models suggest that RX-5902 enhances the efficacy of immunotherapy. We have evaluated RX-5902 in a Phase 1 dose escalation study in patients with a diverse range of metastatic, treatment-refractory tumors, including breast, ovarian, colorectal, and neuro-endocrine tumors.  In February 2017, we initiated a Phase 2a clinical study of RX-5902 in patients with metastatic triple negative breast cancer (“TNBC”).

RX-0201 (Archexin®) is a potential best-in-class, potent inhibitor of the protein kinase Akt-1, which we believe plays a critical role in cancer cell proliferation, survival, angiogenesis, metastasis and drug resistance.  RX-0201 is the subject of a research and development collaboration with Zhejiang Haichang Biotechnology Co., Ltd. (“Haichang”) for the development of RX-0201 for hepatocellular carcinoma. RX-0201 has received orphan drug designation from the FDA for renal cell carcinoma (“RCC”), glioblastoma, ovarian cancer, stomach cancer and pancreatic cancer.

These clinical development programs are part of a growing oncology drug pipeline that consists of highly differentiated and exciting anti-cancer compounds.

Our strategy is to continue building a significant clinical development pipeline of innovative therapies that we will commercialize on our own or with other pharmaceutical partners. Rexahn’s powerful discovery engine and differentiated product pipeline provide the opportunity for a high value generating biopharmaceutical company.


 Rexahn  Pipeline

Management Team

Peter Suzdak, Ph.D.
Chief Executive Officer 

Dr. Peter Suzdak joined Rexahn Pharmaceuticals in February 2013. Dr. Suzdak has over 25 years of diverse experience, including several management positions, in the pharmaceutical industry. Most recently, Dr. Suzdak was Chief Scientific Officer of Corridor Pharmaceuticals, a company developing small molecule compounds to treat pulmonary and vascular disorders. Prior to Corridor Pharmacueitcals, he was co-Founder, Chief Executive Officer and Chief Scientific Officer of Cardioxyl Pharmaceuticals, a company focused on therapies for the treatment of cardiovascular disease. Previous to Cardioxyl Pharmaceuticals, he was President and Chief Executive Officer of Artesian Therapeutics, a company engaged in the development of small molecule therapeutics for cardiovascular diseases. Dr. Suzdak’s experience also includes his position as Senior Vice President of Research and Development of Guilford Pharmaceuticals, a company that developed therapeutics and diagnostics for neurological diseases and cancer, and as Director of Neurobiology for Novo Nordisk. Dr. Suzdak holds a Ph.D. in pharmacology and toxicology from the University of Connecticut.

Rick Soni, MBA
President and Chief Operating Officer

Rick Soni joined Rexahn in 2008 with over 20 years of sales, marketing, product planning and business development experience in the pharmaceutical industry. Prior to joining Rexahn, Mr. Soni held leadership roles at Otsuka America Pharmaceuticals, Inc., with responsibility for commercial development, corporate strategy and execution of licensing and acquisition of therapeutics, diagnostics and medical devices. Previously, Mr. Soni has held a variety of management positions at Novartis and Schering-Plough. Mr. Soni has a BS from the University of Wisconsin-Madison and an MBA from Fairleigh Dickinson University.

Tae Heum (Ted) Jeong, D. Mgt.
Sr. Vice President  and Chief Financial Officer

Dr. Jeong has been Chief Financial Officer of Rexahn Pharmaceuticals since 2002. He oversees all aspects of capital raising, accounting, operations, and corporate development for Rexahn. He is also responsible for investor relations, and played a key role in Rexahn’s 2008 listing on the New York Stock Exchange (NYSE) AMEX. For the past 16 years, he has extensive experience in venture capital and investment banking industry that includes role at Hyundai Venture Investment Corporation where he managed the Biotechnology investment team. Dr. Jeong holds a Doctor of Management from University of Maryland and an M.S. in Finance from Johns Hopkins University

Roth Capital Partners, LLC
      Joseph Pantginis, Ph.D.

Maxim Group, LLC
Echo He, MD, Ph.D.

H. C. Wainwright & Co., LLC
Andrew Fein

Tricia Truehart
(646) 378-2953

Day Range:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PlusOneCoin Top Posts Free PlusOneCoin
No plusone'd posts yet. Be the first!
Post Subject
#3898 11/06/2020: REXN now re-brands with new ticker saturn_five 11/05/2020 08:26:45 PM
#3897 Following closing, which is expected to occur in kpisme 08/28/2020 02:18:54 PM
#3896 Does anybody know when the merger is suppose geenback 08/27/2020 12:44:07 PM
#3895 * * $REXN Video Chart 02-12-2020 * * ClayTrader 02/12/2020 06:18:34 PM
#3894 Total shares traded today 19.6 mill That’s almost 5x ttubular 02/11/2020 06:14:28 PM
#3893 * * $REXN Video Chart 02-11-2020 * * ClayTrader 02/11/2020 05:42:52 PM
#3892 REXN 4.26 hi G2G 02/11/2020 12:15:31 PM
#3891 Over $4 ttubular 02/11/2020 11:50:43 AM
#3890 $3.60 :D wesley_ 02/11/2020 11:10:07 AM
#3889 $3.06 nice wesley_ 02/11/2020 10:58:42 AM
#3888 I am in outstanding 8-k! powerbattles 02/11/2020 10:32:41 AM
#3887 On February 8, 2020, Rexahn Pharmaceuticals, Inc. (the ttubular 02/10/2020 11:09:22 PM
#3886 Nice after hours pop in share price. Made ttubular 02/10/2020 05:39:20 PM
#3885 * * $REXN Video Chart 11-01-2019 * * ClayTrader 11/01/2019 04:09:34 PM
#3884 This company’s pipeline has so much potential. I’ve Crozz 06/19/2019 02:51:06 PM
#3883 Please update the ticker on this board to Crozz 06/19/2019 02:42:07 PM
#3882 Rexahn Announces Move to Nasdaq Crozz 06/19/2019 02:37:57 PM
#3881 Why move to NASDAQ right now? This is Crozz 06/19/2019 02:30:43 PM
#3880 News: $RNN Biotech Brief: Optimism Rising For Cancer whytestocks 04/17/2019 08:31:07 AM
#3879 Right?!? Love that last kick to the crotch DorianGray 04/16/2019 11:25:04 PM
#3878 * * $RNN Video Chart 04-16-2019 * * ClayTrader 04/16/2019 04:53:33 PM
#3877 Massive news on low floater, in with starter UP Trend 04/16/2019 10:06:53 AM
#3876 News: $RNN Rexahn and BioSense Global Announce Collaboration whytestocks 04/16/2019 10:00:48 AM
#3875 could have made some money but instead decided Mistr Tommy 04/16/2019 09:59:35 AM
#3874 Can we get to 174 so I can ttubular 04/16/2019 09:53:03 AM
#3873 It should def run with the big deal airahim 04/16/2019 09:09:20 AM
#3872 I didnt realize there is only 4 million Mistr Tommy 04/16/2019 09:06:20 AM
#3871 Exactly. Could be a crazy run today QuidRunner 04/16/2019 08:57:21 AM
#3870 Yup! We now have a super low floater. crudeoil24 04/16/2019 08:56:29 AM
#3869 Wow, nice... would like to see some circuit QuidRunner 04/16/2019 08:54:04 AM
#3868 ROCKVILLE, Md. and SUZHOU, China, April 16, 2019 crudeoil24 04/16/2019 08:28:36 AM
#3867 1 more reverse and I may owe them kpisme 04/11/2019 04:12:37 PM
#3866 I now need the price to go to ttubular 04/11/2019 12:29:58 PM
#3865 Agreed. What a toilet wipe. kpisme 04/11/2019 11:57:10 AM
#3864 Reverse stock split 1 for 12 This sucks big time ttubular 04/10/2019 04:24:40 PM
#3863 I personally decided to get out on this PennyWorld 02/19/2019 06:05:02 PM
#3862 I understand 100% what your saying. I'm not Crozz 02/19/2019 03:04:39 PM
#3861 I no longer buy penny stocks under $1 PennyWorld 02/15/2019 02:46:20 PM
#3860 I rode out the split in May and HSTN 02/15/2019 02:42:52 PM
#3859 What I was really trying to say is.... PennyWorld 02/11/2019 03:26:34 PM
#3858 I agree with everything you said. What I Crozz 02/11/2019 12:00:47 PM
#3857 disagree.. R/S is not factored into the price. PennyWorld 02/08/2019 05:48:15 PM
#3856 Insiders are executing options, so that they can Crozz 02/08/2019 12:11:07 PM
#3855 If you own shares, Vote against the R/S Crozz 02/08/2019 11:49:25 AM
#3854 DELIST PLEASE this is and will always be kpisme 02/07/2019 05:46:11 PM
#3853 It really doesn't make any difference whether or Crozz 02/07/2019 03:39:38 PM
#3852 Longs don't seem to ever get rewarded here. Crozz 02/07/2019 03:35:56 PM
#3851 I wouldn't get too excited, that was a Crozz 02/07/2019 03:31:19 PM
#3850 WTF...finally some good news! A patent notification...And they Crozz 02/07/2019 03:28:32 PM
#3849 Hold tight....Insiders didn't just buy for no reason. 420man 02/04/2019 08:38:25 AM
Post Subject